Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Caribou Biosciences 14-Day RSI Related Terms
CRBU vs SMNR, ARCT, EQ: 14-Day RSI Comparison
For the Biotechnology subindustry, Caribou Biosciences's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caribou Biosciences 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caribou Biosciences's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Caribou Biosciences's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caribou Biosciences (CRBU) has a 14-Day RSI of 41.00 as of Aug. 19, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Caribou Biosciences and its competitors. According to the industry distribution chart, Caribou Biosciences ranks #273 out of 1418 companies in the Biotechnology industry, placing it in the top 19.3%.
Is Caribou Biosciences' 14-Day RSI too high?
Caribou Biosciences' current 14-Day RSI is 41.00. The Biotechnology industry median 14-Day RSI is 50.68. Caribou Biosciences' value of 41.00 is 19.1% below this industry median. Based on the distribution chart, Caribou Biosciences ranks #273 out of 1418 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Caribou Biosciences has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' 14-Day RSI compare to SMNR and ARCT?
According to the Biotechnology industry distribution chart, Caribou Biosciences ranks #273 out of 1418 companies for 14-Day RSI. This places Caribou Biosciences in the top 19% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 50.68. Caribou Biosciences' value of 41.00 is 19.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 50.68, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caribou Biosciences's current 14-Day RSI of 41.00 is 19.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Caribou Biosciences and its competitors. For the Biotechnology industry, the median 14-Day RSI is 50.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caribou Biosciences's current 14-Day RSI is 41.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.42, compared to a current price of $1.64 — trading 15.1% above its estimated fair value. The current 14-Day RSI is 41.00 and 19.1% below the Biotechnology industry median of 50.68. Caribou Biosciences' overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current 14-Day RSI is 41.00 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caribou Biosciences (CRBU) Overvalued in 2026?
Based on GuruFocus' analysis, Caribou Biosciences stock appears to be overvalued.
The current stock price of $1.64 is trading 15.1% above its estimated GF Value™ of $1.42.
GuruFocus considers Caribou Biosciences to be Modestly Overvalued.
Key valuation signals for CRBU:
14-Day RSI: 41.00
GF Value™: $1.42 vs. price of $1.64 (15.1% above fair value)
Industry Position: 19.1% below the Biotechnology median (#273 of 1418)
No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
64GF Score
Get the complete analysis for CRBU
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRBU has been successfully added to your 
